Timothy Eugene Sullivan's Net Worth
$16.4 Million
Who is Timothy Eugene Sullivan?
Timothy Eugene Sullivan has an estimated net worth of $16.4 Million. This is based on reported shares across multiple companies, which include Apellis Pharmaceuticals, Inc., and G1 Therapeutics, Inc..
SEC CIK
Timothy Eugene Sullivan's CIK is 0001707000
Past Insider Trading and Trends
2023 was Timothy Eugene Sullivan's most active year for acquiring shares with 9 total transactions. Timothy Eugene Sullivan's most active month to acquire stocks was the month of December. 2023 was Timothy Eugene Sullivan's most active year for disposing of shares, totalling 18 transactions. Timothy Eugene Sullivan's most active month to dispose stocks was the month of May. 2023 saw Timothy Eugene Sullivan paying a total of $3,183,898.26 for 245,874 shares, this is the most they've acquired in one year. In 2023 Timothy Eugene Sullivan cashed out on 242,543 shares for a total of $7,841,151.27, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Apellis Pharmaceuticals, Inc. (APLS) Snapshot price: $66.61
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
| 149.57K |
Apr 18
| |||
Form 4
|
—
|
0
|
$34.35 | -$194,520.00 | 93.34K |
Scheduled
|
Apr 1
| ||
Form 4
|
—
|
0
|
$36.63 | -$319,160.00 | 93.34K |
Scheduled
|
Mar 1
| ||
Form 4
| -1.51% | -1.43K |
$67.77 | -$96,974.43 | 93.34K |
Feb 12
| |||
Form 4
| -0.95% | -906.00 |
$64.14 | -$58,109.21 | 94.77K |
Jan 29
| |||
Form 4
| -3.58% | -3.55K |
$65.00 | -$230,800.80 | 95.67K |
Jan 22
| |||
Form 4
| +27.68% | 21.51K |
$66.81 | -$149,317.22 | 99.23K |
Jan 16
| |||
Form 4
|
—
|
0
|
$32.38 | -$632,879.58 | 77.71K |
Scheduled
|
Nov 30
| ||
Form 4
|
—
|
0
|
$50.00 | -$541,934.75 | 77.71K |
Jul 3
| |||
Form 4
|
—
|
0
|
$49.42 | -$5,496,643.49 | 77.71K |
Jun 5
| |||
Form 4
|
—
|
0
|
—
|
—
| 133.94K |
May 3
| |||
Form 4
|
—
|
0
|
—
|
—
| 133.94K |
Apr 19
| |||
Form 4
| +8.69% | 10.71K |
$58.50 | -$56,979.00 | 133.94K |
Feb 21
| |||
Form 4
| -0.78% | -975.00 |
$51.21 | -$49,929.75 | 123.24K |
Feb 10
| |||
Form 4
| -0.44% | -551.00 |
$52.77 | -$29,076.27 | 124.21K |
Jan 27
| |||
Form 4
| -1.87% | -2.38K |
$52.05 | -$123,826.95 | 124.76K |
Jan 20
| |||
Form 4
| +22.96% | 23.74K |
—
|
—
| 127.14K |
Apr 25 - Jan 12
| |||
Form 4
| -0.84% | -875.00 |
$47.12 | -$41,230.00 | 103.4K |
Feb 10
| |||
Form 4
| -0.62% | -650.00 |
$38.59 | -$25,083.50 | 104.28K |
Jan 28
| |||
Form 4
| +41.52% | 30.79K |
—
|
—
| 104.93K |
Jan 21
| |||
Form 4
| +116.40% | 39.88K |
$10.03 | $399,996.40 | 74.14K |
Jun 8
| |||
Form 4
| -2.44% | -858.00 |
$47.72 | -$40,943.76 | 34.26K |
Feb 10
| |||
Form 4
| +47.13% | 11.25K |
—
|
—
| 35.12K |
Jan 28
| |||
Form 4
| +99.91% | 11.69K |
—
|
—
| 23.39K |
Feb 10
| |||
Form 4
|
∞
| 11.7K |
$29.71 | $347,629.94 | 11.7K |
Aug 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
G1 Therapeutics, Inc. (GTHX) Snapshot price: $4.77
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||